CDO1 and laryngotracheoesophageal cleft: Ooki et al. used a panel of 6 genes (CDO1, HOXA9, AJAP1, PTGDR, UNCX, and MARCH11) as a powerful biomarker to distinguish between LC patients and healthy controls, which had a sensitivity of over 90% for diagnosing of stage IA NSCLC [47].